Tempus CRC 监测研究:使用 NGS 分析对 CRC 患者进行的 ctDNA 生物标志物分析研究
2024年4月2日 更新者:Tempus AI
Tempus CRC 监测研究:使用全面的下一代测序 (NGS) 分析对结直肠癌 (CRC) 患者进行纵向循环肿瘤 DNA (ctDNA) 生物标志物分析研究
该研究是对结直肠癌 (CRC) 参与者的观察性多中心评估,除了他们的标准护理治疗和疾病监测外,他们还将接受纵向血浆 ctDNA 生物标志物分析。
研究概览
研究类型
观察性的
注册 (估计的)
160
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:CRC Surveillance Study
- 电话号码:(833) 514-4187
- 邮箱:gemini-crc@tempus.com
学习地点
-
-
Arkansas
-
Fort Smith、Arkansas、美国、72903
- 招聘中
- Mercy Clinic Oncology - Fort Smith
-
接触:
- Billy Cater
- 邮箱:Billy.Cater@mercy.net
-
首席研究员:
- Aswanth Reddy, MD
-
-
California
-
Fountain Valley、California、美国、92708
- 招聘中
- MemorialCare
-
接触:
- Laura Macias
- 电话号码:562-706-2701
- 邮箱:LMacias@memorialcare.org
-
首席研究员:
- Amol Rao, MD
-
-
Maryland
-
Bethesda、Maryland、美国、20817
- 招聘中
- The Center for Cancer and Blood Disorders
-
首席研究员:
- Mark Goldstein, MD
-
接触:
- Kosunique Jenkins
- 电话号码:301-571-2016
- 邮箱:kosunique.jenkins@tempus.com
-
-
Missouri
-
Joplin、Missouri、美国、64804
- 招聘中
- Mercy Clinic Oncology and Hematology - Joplin
-
首席研究员:
- Samir Dalia, MD
-
接触:
- Cynthia Meyer
- 邮箱:Cynthia.Meyer@mercy.net
-
Saint Louis、Missouri、美国、63110
- 招聘中
- Washington University School of Medicine
-
接触:
- Mary Pecoraro
- 电话号码:314-273-0884
- 邮箱:mpecoraro@wustl.edu
-
首席研究员:
- Ryan Fields, MD
-
Saint Louis、Missouri、美国、63128
- 招聘中
- Mercy Clinic Oncology and Hematology - Sindelar Cancer Center
-
接触:
- Jessica Black
- 邮箱:Jessica.Black@mercy.net
-
首席研究员:
- Yifan Tu, MD
-
Saint Louis、Missouri、美国、63141
- 招聘中
- Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center
-
首席研究员:
- Bethany Sleckman, MD
-
接触:
- Emily Hoven
- 邮箱:Emily.Hoven@Mercy.Net
-
Springfield、Missouri、美国、65804
- 招聘中
- Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center
-
接触:
- Jennifer Hylton
- 邮箱:Jennifer.Hylton@mercy.net
-
首席研究员:
- Mohan Tummala, MD
-
-
Nebraska
-
Omaha、Nebraska、美国、68130
- 招聘中
- Nebraska Cancer Specialists
-
首席研究员:
- Timothy Huyck, MD
-
接触:
- Brenda Broekemeier
- 电话号码:308-218-6324
- 邮箱:bbroekemeier@nebraskacancer.com
-
-
North Carolina
-
Goldsboro、North Carolina、美国、27543
- 招聘中
- Southeastern Medical Oncology Center
-
接触:
- Jennifer Fields
- 电话号码:919-587-9084
- 邮箱:jfields@cancersmoc.com
-
首席研究员:
- Samer Kasbari, MD
-
-
Ohio
-
Canton、Ohio、美国、44710
- 招聘中
- Aultman Hospital
-
接触:
- Kristin Shine
- 邮箱:Kristin.Shine@aultman.com
-
首席研究员:
- Adarsh Vennepureddy, MD
-
Cincinnati、Ohio、美国、45220
- 招聘中
- TriHealth Cancer Institute
-
首席研究员:
- Benjamin Kuritzky, MD
-
接触:
- Wayne Thompson
- 电话号码:513-865-5020
- 邮箱:Wayne_Thompson@trihealth.com
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University
-
接触:
- Jennifer Moon
- 邮箱:jennifer.moon@osumc.edu
-
首席研究员:
- Arjun Mittra, MD
-
Columbus、Ohio、美国、43214
- 招聘中
- OhioHealth Research Institute
-
首席研究员:
- Avinder Bhinder, MD
-
接触:
- Kevin Miller
- 电话号码:614-788-3886
- 邮箱:Kevin.Miller@ohiohealth.com
-
Toledo、Ohio、美国、43623
- 招聘中
- Toledo Clinic Cancer Center
-
首席研究员:
- Ahmad Zarzour, MD
-
接触:
- Pam Shoup
- 电话号码:419-214-4236
- 邮箱:PShoup@toledoclinic.com
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73120
- 招聘中
- Mercy Clinic Oncology and Hematology - Coletta
-
接触:
- Patricia Strubhar
- 邮箱:Patricia.Strubhar@mercy.net
-
首席研究员:
- Carla Kurkjian, MD
-
-
Pennsylvania
-
York、Pennsylvania、美国、17403
- 招聘中
- Cancer Care Associates of York
-
首席研究员:
- Chanh Huynh, MD
-
接触:
- Jennifer Stough
- 电话号码:717-741-9229
- 邮箱:jstough@cancercareyork.com
-
-
Utah
-
Salt Lake City、Utah、美国、84124
- 招聘中
- Utah Cancer Specialists
-
接触:
- Angela Nuttall
- 电话号码:801-267-5606
- 邮箱:anuttall@utahcancer.com
-
首席研究员:
- Kyle Kitchen, Pharm-D
-
-
Washington
-
Seattle、Washington、美国、98109
- 招聘中
- University of Washington / Fred Hutchinson Cancer Center
-
首席研究员:
- Stacey Cohen, MD
-
接触:
- Bentina Marin
- 邮箱:amarin@fredhutch.org
-
-
Wisconsin
-
Appleton、Wisconsin、美国、54911
- 招聘中
- ThedaCare Regional Cancer Center
-
首席研究员:
- Matthias Weiss, MD, PhD
-
接触:
- Rachel Luedtke
- 电话号码:920-364-3616
- 邮箱:Rachel.Luedtke@thedacare.org
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
取样方法
非概率样本
研究人群
该方案针对 I-IV 期结直肠癌 (CRC) 患者
描述
纳入标准:
- 已知或疑似结直肠腺癌(I 至 IV 期疾病)
- 计划接受或已经接受以治愈为目的的疑似结肠或直肠腺癌手术切除。
- 18岁或以上
- 愿意并能够提供知情同意
- 愿意在常规监测访问期间收集额外的血样
排除标准:
- 不愿意采集额外的血样
- 不符合结直肠腺癌的病理学
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
患有 I-IV 期结直肠癌 (CRC) 的参与者
该方案将包括 I-IV 期 CRC 的参与者,他们计划接受或已经接受以治愈为目的的手术切除。
|
无干预
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
无复发生存期
大体时间:2年
|
通过标准放射成像评估的无复发生存期,从确定性治疗完成之日到第一次放射成像复发或死亡
|
2年
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
灵敏度
大体时间:2年
|
敏感性定义为检测到 ctDNA 的复发参与者的比例。
|
2年
|
阳性预测值
大体时间:2年
|
阳性预测值 (PPV) 定义为检测到 ctDNA 的参与者复发的比例。
|
2年
|
特异性
大体时间:2年
|
特异性定义为未检测到 ctDNA 而未复发的参与者的比例。
|
2年
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
---|---|---|
交货时间
大体时间:2年
|
提前期定义为 ctDNA 检测与临床检测复发之间的间隔。
|
2年
|
总生存期
大体时间:2 年或直到报告患者死亡
|
因任何原因从入组到死亡之间的时间间隔
|
2 年或直到报告患者死亡
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
调查人员
- 首席研究员:Kristiyana Kaneva, MD, MS、Tempus AI, Inc.
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi: 10.1038/nrclinonc.2013.110. Epub 2013 Jul 9.
- Normanno N, Cervantes A, Ciardiello F, De Luca A, Pinto C. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Cancer Treat Rev. 2018 Nov;70:1-8. doi: 10.1016/j.ctrv.2018.07.007. Epub 2018 Jul 18.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
- Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, Kanter K, Fish MG, Fosbenner KD, Miao B, Phillips S, Carmichael JH, Sharma N, Jarnagin J, Baiev I, Shah YS, Fetter IJ, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Dubois JS, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, Nipp RD, Roeland EJ, Ryan DP, Weekes CD, Wo JY, Hong TS, Bordeianou L, Ferrone CR, Qadan M, Kunitake H, Berger D, Ricciardi R, Cusack JC, Raymond VM, Talasaz A, Boland GM, Corcoran RB. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021 Oct 15;27(20):5586-5594. doi: 10.1158/1078-0432.CCR-21-0410. Epub 2021 Apr 29.
- Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Robertson DJ, Rex DK; United States Multi-Society Task Force on Colorectal Cancer. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016 Mar;150(3):758-768.e11. doi: 10.1053/j.gastro.2016.01.001. Epub 2016 Feb 10.
- Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, Andre T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum In: Lancet Oncol. 2017 Sep;18(9):e510.
- Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906.
- Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019 Jun 13;38(1):255. doi: 10.1186/s13046-019-1259-z.
- Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskjot L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528. Erratum In: JAMA Oncol. 2019 Jun 13;:
- Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. doi: 10.1038/nrclinonc.2017.14. Epub 2017 Mar 2.
- Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.
- Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014 Apr 26;383(9927):1490-1502. doi: 10.1016/S0140-6736(13)61649-9. Epub 2013 Nov 11.
- Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020 May;70(3):145-164. doi: 10.3322/caac.21601. Epub 2020 Mar 5.
- Richman SD, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G, Quirke P. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst). 2011;34(1-2):61-6. doi: 10.3233/ACP-2011-0005.
- Stoffel EM, Murphy CC. Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults. Gastroenterology. 2020 Jan;158(2):341-353. doi: 10.1053/j.gastro.2019.07.055. Epub 2019 Aug 5.
- Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL, Zhao J, Anderson RN, Henley SJ, Yabroff KR, Jemal A, Benard VB. Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics. J Natl Cancer Inst. 2021 Nov 29;113(12):1648-1669. doi: 10.1093/jnci/djab131.
- Institute NC, National Cancer Institute. AJCC Cancer Staging Manual 8th Edition. Definitions. 2020
- Leufkens AM, van den Bosch MA, van Leeuwen MS, Siersema PD. Diagnostic accuracy of computed tomography for colon cancer staging: a systematic review. Scand J Gastroenterol. 2011 Jul;46(7-8):887-94. doi: 10.3109/00365521.2011.574732. Epub 2011 Apr 20.
- Benson AB 3rd, Choti MA, Cohen AM, Doroshow JH, Fuchs C, Kiel K, Martin EW Jr, McGinn C, Petrelli NJ, Posey JA, Skibber JM, Venook A, Yeatman TJ; National Comprehensive Cancer Network. NCCN Practice Guidelines for Colorectal Cancer. Oncology (Williston Park). 2000 Nov;14(11A):203-12.
- Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997 Feb;112(2):594-642. doi: 10.1053/gast.1997.v112.agast970594. No abstract available. Erratum In: Gastroenterology 1997 Mar;112(3):1060. Gastroenterology 1998 Mar;114(3):625.
- Provenzale D, Ness RM, Llor X, Weiss JM, Abbadessa B, Cooper G, Early DS, Friedman M, Giardiello FM, Glaser K, Gurudu S, Halverson AL, Issaka R, Jain R, Kanth P, Kidambi T, Lazenby AJ, Maguire L, Markowitz AJ, May FP, Mayer RJ, Mehta S, Patel S, Peter S, Stanich PP, Terdiman J, Keller J, Dwyer MA, Ogba N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1312-1320. doi: 10.6004/jnccn.2020.0048.
- Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for Colorectal Cancer Screening. Gastroenterology. 2020 Jan;158(2):418-432. doi: 10.1053/j.gastro.2019.06.043. Epub 2019 Aug 5.
- Muller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016 Aug;469(2):125-34. doi: 10.1007/s00428-016-1956-3. Epub 2016 Jun 20.
- Poulogiannis G, Ichimura K, Hamoudi RA, Luo F, Leung SY, Yuen ST, Harrison DJ, Wyllie AH, Arends MJ. Prognostic relevance of DNA copy number changes in colorectal cancer. J Pathol. 2010 Feb;220(3):338-47. doi: 10.1002/path.2640.
- Arends MJ. Pathways of colorectal carcinogenesis. Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):97-102. doi: 10.1097/PAI.0b013e31827ea79e.
- Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology. 2010 Jan;56(2):167-79. doi: 10.1111/j.1365-2559.2009.03392.x.
- Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, Syngal S, Rex DK. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum. 2014 Aug;57(8):1025-48. doi: 10.1097/DCR.000000000000000.
- Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espin E, Armengol M, Sijmons RH, Kleibeuker JH, Seruca R, Aaltonen LA, Imai K, Yamamoto H, Schwartz S Jr, Hofstra RM. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene. 2005 Jun 2;24(24):3995-8. doi: 10.1038/sj.onc.1208569.
- Morse MA, Hochster H, Benson A. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. Oncologist. 2020 Jan;25(1):33-45. doi: 10.1634/theoncologist.2019-0176. Epub 2019 Aug 5.
- Gourd E. Nivolumab plus ipilimumab in metastatic colorectal cancer. Lancet Oncol. 2018 Mar;19(3):e139. doi: 10.1016/S1470-2045(18)30067-6. Epub 2018 Jan 26. No abstract available.
- Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, Andre T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
- Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009;4:343-64. doi: 10.1146/annurev.pathol.4.110807.092317.
- Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30.
- Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessi M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers (Basel). 2020 May 13;12(5):1214. doi: 10.3390/cancers12051214.
- Kolencik D, Shishido SN, Pitule P, Mason J, Hicks J, Kuhn P. Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges. Cancers (Basel). 2020 May 27;12(6):1376. doi: 10.3390/cancers12061376.
- Kasi PM, Sawyer S, Guilford J, Munro M, Ellers S, Wulff J, Hook N, Krinshpun S, Koyen Malashevich A, Malhotra M, Rodriguez A, Moshkevich S, Grothey A, Kopetz S, Billings P, Aleshin A. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open. 2021 Sep 24;11(9):e047831. doi: 10.1136/bmjopen-2020-047831.
- Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Janne PA, Paweletz CP, Oxnard GR. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res. 2018 Sep 15;24(18):4437-4443. doi: 10.1158/1078-0432.CCR-18-0143. Epub 2018 Mar 22.
- Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, Bobe AM, Bush S, Chang AL, Hoskinson DC, Khan AA, Kudalkar E, Leibowitz BD, Lozachmeur A, Michuda J, Parsons J, Perera JF, Salahudeen A, Shah KP, Taxter T, Zhu W, White KP. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019 Nov;37(11):1351-1360. doi: 10.1038/s41587-019-0259-z. Epub 2019 Sep 30.
- Beaubier N, Tell R, Lau D, Parsons JR, Bush S, Perera J, Sorrells S, Baker T, Chang A, Michuda J, Iguartua C, MacNeil S, Shah K, Ellis P, Yeatts K, Mahon B, Taxter T, Bontrager M, Khan A, Huether R, Lefkofsky E, White KP. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019 Mar 22;10(24):2384-2396. doi: 10.18632/oncotarget.26797. eCollection 2019 Mar 22.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2022年6月21日
初级完成 (估计的)
2025年2月1日
研究完成 (估计的)
2027年2月1日
研究注册日期
首次提交
2022年1月31日
首先提交符合 QC 标准的
2022年1月31日
首次发布 (实际的)
2022年2月10日
研究记录更新
最后更新发布 (实际的)
2024年4月3日
上次提交的符合 QC 标准的更新
2024年4月2日
最后验证
2024年4月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.